Last reviewed · How we verify

Wee-1 kinase inhibitor AZD1775

AstraZeneca · Phase 1 active Small molecule

Wee-1 kinase inhibitor AZD1775 is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development.

At a glance

Generic nameWee-1 kinase inhibitor AZD1775
SponsorAstraZeneca
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Wee-1 kinase inhibitor AZD1775

What is Wee-1 kinase inhibitor AZD1775?

Wee-1 kinase inhibitor AZD1775 is a Small molecule drug developed by AstraZeneca.

Who makes Wee-1 kinase inhibitor AZD1775?

Wee-1 kinase inhibitor AZD1775 is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What development phase is Wee-1 kinase inhibitor AZD1775 in?

Wee-1 kinase inhibitor AZD1775 is in Phase 1.

Related